Intersect Ent Inc Revenue Growth Rates (XENT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intersect Ent Inc   (NASDAQ: XENT)
 

XENT's Revenue Growth by Quarter and Year

Intersect Ent Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XENT Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 21.58
FY 21.58

XENTs Annual Revenue
Intersect Ent Inc 's Revenue in the fiscal year 2021 $ 106.75 millions
Intersect Ent Inc 's Revenue in the fiscal year 2020 $ 80.55 millions
Intersect Ent Inc 's Revenue in the fiscal year 2019 $ 109.14 millions
Intersect Ent Inc 's Revenue in the fiscal year 2018 $ 108.47 millions
Intersect Ent Inc 's Revenue in the fiscal year 2017 $ 96.30 millions




XENT Revenue first quarter 2022 Y/Y Growth Comment
Intersect Ent Inc reported fall in Revenue in the first quarter 2022 by -11.32% to $ 21.58 millions, from the same quarter in 2021.
The decline in the first quarter 2022 Intersect Ent Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 18.24%.

Looking into first quarter 2022 results within Medical Equipment & Supplies industry 141 other companies have achieved higher Revenue growth. While Intersect Ent Inc ' s Revenue decrease of -11.32% ranks overall at the positon no. 3306 in the first quarter 2022.


XENT Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 8.64 % -11.09 % -3.14 %
3rd Quarter September - 7.39 % -5.57 % -2.47 %
2nd Quarter June - 179.65 % -63.32 % 1.37 %
1st Quarter March -11.32 % 22.69 % -25.65 % 7.89 %
FY   - 32.51 % -26.19 % -

Financial Statements
Intersect Ent Inc 's first quarter 2022 Revenue $ 21.58 millions XENT's Income Statement
Intersect Ent Inc 's first quarter 2021 Revenue $ 24.33 millions Quarterly XENT's Income Statement


XENT Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 25.7 % 24.25 % 31.96 %
3rd Quarter September - -10.79 % 132.31 % -9.75 %
2nd Quarter June - 12.41 % -50.68 % -0.04 %
1st Quarter March -29.65 % -13.82 % -37.54 % -18.64 %
FY (Year on Year)   - 32.51 % -26.19 % -


Back to XENT Growth rate Comparisons >> Back to XENT Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #142
Healthcare Sector #493
Overall #3306

Revenue Y/Y Growth Statistics
High Average Low
179.64 % 18.24 % -63.31 %
(Dec. 30, 2015)   (Jun 30 2020)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #142
Healthcare Sector #493
Overall #3306
Revenue Y/Y Growth Statistics
High Average Low
179.64 % 18.24 % -63.31 %
(Dec. 30, 2015)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Intersect Ent Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
132.31 % 6.23 % -50.67 %
(Sep 30 2020)  


XENT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Intersect Ent Inc disclosed fall in Revenue from the fourth quarter by -29.65% to $ 21.58 millions, from $ 30.67 millions achived in the previous reporting period.

But that's not important problem, as Intersect Ent Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 136 other companies have achieved higher Revenue quarter on quarter growth. While Intersect Ent Inc 's Revenue growth quarter on quarter, overall rank is 3642.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #137
Healthcare Sector #559
Overall #3642
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #137
Healthcare Sector #559
Overall #3642
Revenue Q/Q Growth Statistics
High Average Low
132.31 % 6.23 % -50.67 %
(Sep 30 2020)  


XENT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2022 Intersect Ent Inc disclosed fall in Revenue from the fourth quarter by -29.65% to $ 21.58 millions, from $ 30.67 millions achived in the previous reporting period.

But that's not important problem, as Intersect Ent Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 136 other companies have achieved higher Revenue quarter on quarter growth. While Intersect Ent Inc 's Revenue growth quarter on quarter, overall rank is 3642.


Intersect Ent Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 103.99 $ 106.75 $ 104.31 $ 102.63 $ 85.06
Y / Y Revenue Growth (TTM) 22.27 % 32.52 % 24.05 % 20.15 % -16.85 %
Year on Year Revenue Growth Overall Ranking # 3370 # 743 # 1012 # 954 # 2091
Seqeuential Revenue Change (TTM) -2.58 % 2.34 % 1.64 % 20.66 % 5.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 2684 # 1757 # 2585 # 514 # 3214


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2022 period, Intersect Ent Inc 's cumulative twelve months Revenue were $ 104 millions, company would post below average annual Revenue growth of 5.59% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Intersect Ent Inc 's Revenue growth from the 30.67% growth in Dec 31 2021.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 743 to 3370.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 458
Overall # 3370

Revenue TTM Y/Y Growth Statistics
High Average Low
3338.2 %
 158.66 %
-26.19 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2684
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2022 period, Intersect Ent Inc 's cumulative twelve months Revenue were $ 104 millions, company would post below average annual Revenue growth of -26.19% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Intersect Ent Inc 's Revenue growth from the 30.67% growth in Dec 31 2021.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 743 to 3370.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 458
Overall # 3370

Revenue TTM Y/Y Growth Statistics
High Average Low
3338.2 %
158.66 %
-26.19 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2684




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XENT's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Sage Therapeutics Inc -0.06%$ -0.063 millions
Davita Inc -0.09%$ -0.087 millions
Axogen inc -0.10%$ -0.097 millions
Musclepharm Corporation-0.15%$ -0.152 millions
3m Company-0.25%$ -0.249 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical Inc -0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp -0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Assure Holdings Corp -1.34%$ -1.343 millions
Elanco Animal Health Incorporated-1.37%$ -1.369 millions
Longeveron Inc -1.60%$ -1.596 millions
Rockwell Medical inc -1.67%$ -1.674 millions
Nanostring Technologies Inc -1.70%$ -1.698 millions
Mimedx Group Inc -1.79%$ -1.789 millions
Exagen Inc -1.82%$ -1.823 millions
Cryoport inc -1.84%$ -1.843 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Femasys Inc -2.55%$ -2.545 millions
Delcath Systems Inc -2.58%$ -2.577 millions
Imagenebio Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc -2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc -3.18%$ -3.178 millions
Becton Dickinson And Company-3.20%$ -3.200 millions


About Intersect Ent Inc Revenue Growth Rates (XENT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intersect Ent Inc (CIK 1271214).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001271214-22-000024
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intersect Ent Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.